Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	73.37T -5.9%
Revenue (ttm)	4.56T +30.3%
Net Income	1.78T +64.7%
EPS	n/a
Shares Out	46.29M
PE Ratio	41.12
Forward PE	41.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,864
Average Volume	52,171
Open	1,578,000
Previous Close	1,547,000
Day's Range	1,540,000 - 1,607,000
52-Week Range	1,501,000 - 1,987,000
Beta	0.21
RSI	45.24
Earnings Date	Apr 29, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical te...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,195
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2025, Samsung Biologics's revenue was 4.56 trillion, an increase of 30.31% compared to the previous year's 3.50 trillion. Earnings were 1.78 trillion, an increase of 64.71%.